Colorectal CancerNCT06172049
Incidence of Colorectal Cancer in Southwest China: Based on SCC Database
An observational study of Colorectal Cancer, run by West China Hospital at 1 site in China.
Trial summary
To evaluate recent trends in CRC incidence, treatment, and survival in the Southwest China. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Colorectal Cancer
- What is being tested?
- treatment
- How many people
- 5,838 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2014to 31 Oct 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients who were diagnosed with CRC were included
Who may be able to join
- Clinical diagnosis of colorectal cancer;
- Received treatment in medical institutions;
- Regular follow-up after the diagnosis.
Who cannot join
- Patients who lost to follow-up
Trial locations and contacts
1 site in 1 country.
About this study
To evaluate recent trends in CRC incidence, treatment, and survival in the Southwest China.
Read the detailed description
The epidemiological feature of colorectal cancer (CRC) showed different trends among countries. Studying the epidemiological and management characteristics between China and the US has important implications for understanding the current status of cancer occurrence, treatment and survival. we established the Southwest China Colorectal (SCC) database, aiming to provide reference information on the diagnosis and management of CRC in China.
- Conditions
- Colorectal Cancer
- Being tested
- treatment
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
treatmentOther
the actual treatment CRC patients have reveived
| Study group | Role | What they receive |
|---|---|---|
| CRC cases | Not described Receives: Other: treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Survival
Overall survival (OS) untile the end of follow up
Measured: From inclusion until date of death from any cause, or untile the 2023-10-31
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Dec 2023
- Study start1 Jan 2014
- Primary completion31 Dec 2017
- Study completion31 Oct 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- More trials run by West China HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 5,838 participants (actual)
Sponsor and investigators
- Lead sponsor
- West China Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ziqiang Wang,MD, West China Hospital
- Investigators
- Ziqiang Wang, Study chair, West China Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06172049
- Sponsor's protocol ID
- CRC-2023
- Status last verified
- Dec 2023
- First submitted
- 6 Dec 2023
- Last updated
- 15 Dec 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Incidence of Colorectal Cancer in Southwest China: Based on SCC Database
- ClinicalTrials.gov ID
- NCT06172049
- Acronym / sponsor ID
- CRC-2023
- Conditions
- Colorectal Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 5,838 participants (actual)
- Lead sponsor
- West China HospitalUniversity, hospital or other
- Study start
- 1 Jan 2014 (actual)
- Primary completion
- 31 Dec 2017 (actual)
- Study completion
- 31 Oct 2023 (actual)
- First posted
- 15 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate recent trends in CRC incidence, treatment, and survival in the Southwest China.
Detailed description
The epidemiological feature of colorectal cancer (CRC) showed different trends among countries. Studying the epidemiological and management characteristics between China and the US has important implications for understanding the current status of cancer occurrence, treatment and survival. we established the Southwest China Colorectal (SCC) database, aiming to provide reference information on the diagnosis and management of CRC in China.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CRC cases | – | Other: treatment |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients who were diagnosed with CRC were included
Key inclusion criteria (3 listed)
- Clinical diagnosis of colorectal cancer;
- Received treatment in medical institutions;
- Regular follow-up after the diagnosis.
Key exclusion criteria (1 listed)
- Patients who lost to follow-up
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| treatmentthe actual treatment CRC patients have reveived | Other | CRC cases |
Primary outcome
Survival
Time frame: From inclusion until date of death from any cause, or untile the 2023-10-31
Overall survival (OS) untile the end of follow up
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Dec 2023.
- Individual participant dataSharing planned: No
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ziqiang Wang study chair
West China Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Cancer, run by West China Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Survival (time frame: From inclusion until date of death from any cause, or untile the 2023-10-31). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2023.